Jim Wassil compensation by year
Vaxcyte Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $29,167 | $369,643 | $451,800 | $485,685 | $508,000 | $550,000 | $600,000 |
| Bonus | $0 | $240,000 | $0 | $43,711 | — | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $619,750 | $1,223,275 | $7,290,819 | $1,927,501 |
| Option awards | $443,385 | $586,489 | $1,310,708 | $5,545,155 | $3,656,894 | $10,011,989 | $3,267,740 |
| Non-equity incentive | $8,750 | $161,417 | $207,828 | $284,126 | $50 | $10 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | — | $0 | $0 |
| All other | $0 | $0 | $0 | $12,776 | $12,996 | $14,799 | $14,730 |
| Total | $481,302 | $1,357,549 | $1,970,336 | $6,991,203 | $5,401,215 | $17,867,617 | $5,809,971 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vaxcyte, Inc. DEF 14A filed April 23, 2026, accession 0001193125-26-173672, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Vaxcyte, Inc. filed document, accession 0001193125-26-173672. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 35,661 | $1,645,399 | — |
| RSU | 16,294 | $751,805 | — |
| RSU | 10,000 | $461,400 | — |
| RSU | 5,625 | $259,538 | — |
| Option | 57,425 | — | $74.22 |
| Option | 42,188 | — | $41.67 |
| Option | 2,084 | — | $24.79 |
| Option | 9,375 | — | $24.79 |
| Option | 10,500 | — | $47.95 |
| Option | 48,750 | — | $73.82 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Vaxcyte, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
34 Form 4 lines since the FY2025 proxy (filed April 23, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-11-02 | Sale | 10b5-1 | 1,907 | $60.78 | 145,778 |
| 2026-11-02 | Exercise or conversion derivative | 10b5-1 | 2,250 | $0.00 | 44,148 |
| 2026-11-02 | Exercise or conversion | 10b5-1 | 2,250 | $5.35 | 147,685 |
| 2026-11-02 | Sale | 10b5-1 | 343 | $61.57 | 145,435 |
| 2026-10-05 | Exercise or conversion | 10b5-1 | 18,000 | $5.35 | 163,435 |
| 2026-10-05 | Exercise or conversion derivative | 10b5-1 | 18,000 | $0.00 | 46,398 |
| 2026-10-05 | Sale | 10b5-1 | 18,000 | $86.74 | 145,435 |
| 2026-10-01 | Sale | 10b5-1 | 2,155 | $56.65 | 145,530 |
The 8 most recent of 34 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Vaxcyte discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Resignation for good reason, no change in control | $600,000 | $0 | $40,538 | $940,538 |
| Change in control and involuntary termination | $900,000 | $1,905,973 | $60,807 | $3,316,780 |
Per the Potential Payments Upon Termination or Change in Control table in Vaxcyte, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Vaxcyte’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Grant Pickering | Chief Executive Officer | $14,458,937 |
| Andrew Guggenhime | President and Chief Financial Officer | $6,072,939 |
| Jim Wassil · this page | Executive Vice President and Chief Operating Officer | $5,809,971 |
| Mikhail Eydelman | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | $4,005,935 |
| Harp Dhaliwal | Chief Technical Operations Officer | $3,764,679 |
Jim Wassil's compensation dossier, Vaxcyte
You have read Jim Wassil's totals and holdings. The dossier adds each equity grant Vaxcyte disclosed for Jim Wassil and Vaxcyte's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Vaxcyte compensation record
free company briefThis page is one person within Vaxcyte's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Vaxcyte proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Vaxcyte's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vaxcyte's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order PCVX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.